GNH USA

Europe — EMA

Janecluc (Metformin Hydrochloride, Sitagliptin)

GNH USA supplies Janecluc (Metformin and Sitagliptin), a Biguanide and DPP‑4 inhibitor for type 2 diabetes mellitus. Request a quote for global supply.

Metformin Hydrochloride, Sitagliptin

Request sourcing

1
Pack/s

What is Metformin Hydrochloride, Sitagliptin?

Metformin Hydrochloride and Sitagliptin, the active ingredient in Janecluc, is a Biguanide; DPP‑4 inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adults.

GNH USA supplies Janecluc as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

What is Metformin Hydrochloride, Sitagliptin used for?

Janecluc is an oral antidiabetic combination that targets hyperglycaemia in type 2 diabetes mellitus.

- Type 2 diabetes mellitus (initial therapy): provides improved glycaemic control as first‑line treatment. - Type 2 diabetes mellitus (add‑on therapy): enhances glucose lowering when metformin alone is insufficient. - Type 2 diabetes mellitus (dual therapy): offers combined biguanide and DPP‑4 inhibition for patients requiring multiple mechanisms of action.

What are the side effects of Metformin Hydrochloride, Sitagliptin?

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or flatulence. - Diarrhoea: loose stools occurring especially after dose initiation. - Headache: mild to moderate intensity. - Upper respiratory tract infection: cold‑like symptoms. - Fatigue: feeling of tiredness without exertion.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially fatal metabolic disturbance. - Severe hypoglycaemia: especially when combined with insulin or sulfonylureas. - Pancreatitis: acute inflammation of the pancreas. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic dysfunction: marked elevation of liver enzymes.

What precautions apply to Metformin Hydrochloride, Sitagliptin?

Before initiating Janecluc, clinicians should assess patient suitability and monitor for adverse outcomes. - Renal function: evaluate eGFR and avoid use in severe renal impairment. - Hepatic status: check liver enzymes; use cautiously in hepatic disease. - Risk of lactic acidosis: avoid in conditions predisposing to hypoxia. - Elderly patients: start at lower dose and monitor tolerance. - Concomitant medications: review for drugs that may affect glucose levels. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

What does Metformin Hydrochloride, Sitagliptin interact with?

Janecluc may interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Iodinated contrast agents: can precipitate renal failure, increasing metformin accumulation. - Cimetidine: raises sitagliptin plasma concentrations, heightening risk of side effects. - Rifampin: markedly reduces sitagliptin exposure, diminishing efficacy.

Moderate Interactions (Monitor Closely): - Diuretics: may affect renal clearance of metformin. - ACE inhibitors or ARBs: combined effect on renal function warrants monitoring. - NSAIDs: can impair renal function, increasing metformin levels. - Alcohol: potentiates risk of lactic acidosis. - Beta‑blockers: may mask hypoglycaemia symptoms.

Frequently asked questions

What is Janecluc used for?+
Janecluc is a prescription oral medication that combines metformin and sitagliptin to improve blood glucose control in adults with type 2 diabetes mellitus, either as initial therapy or when additional glucose‑lowering effect is needed.
How does Metformin Hydrochloride and Sitagliptin work?+
Metformin decreases hepatic glucose output and enhances insulin sensitivity, while sitagliptin blocks the DPP‑4 enzyme, prolonging incretin activity that stimulates insulin release and reduces glucagon secretion, together lowering blood sugar levels.
What is the usual dose of Janecluc?+
The dose of Janecluc is individualized by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.
Is Janecluc safe during pregnancy or breastfeeding?+
Safety of Janecluc in pregnancy or lactation has not been definitively established. Healthcare providers should weigh potential benefits against risks and consider alternative treatments if appropriate for pregnant or nursing women.
How do I order Janecluc from GNH USA?+
To request Janecluc, submit an enquiry on the product page at gnh-usa.com specifying the required quantity. GNH USA works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.
How does Janecluc compare with other antidiabetic options?+
Janecluc offers the combined mechanisms of a biguanide and a DPP‑4 inhibitor in a single tablet, which can simplify regimens compared with taking separate agents. It may provide better glycaemic control than metformin alone and avoids the injectable route required for some GLP‑1 analogues.
What are the storage requirements for Janecluc?+
Janecluc should be stored at room temperature, below 25 °C, in its original packaging. Keep the tablets away from moisture, heat and direct sunlight to maintain product stability.
How is Janecluc administered?+
Janecluc is taken orally, usually once daily with or after a meal. The tablet should be swallowed whole with water and not chewed or crushed unless otherwise directed by a healthcare professional.
What are the most serious risks associated with Janecluc?+
The most serious risks include lactic acidosis from metformin, severe hypoglycaemia when combined with insulin or sulfonylureas, pancreatitis, and rare severe skin reactions such as Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience symptoms suggestive of these conditions.
Who should not use Janecluc?+
Janecluc is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), known hypersensitivity to metformin or sitagliptin, and in those with a history of lactic acidosis. Caution is also advised for individuals with hepatic disease or significant cardiac failure.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Metformin Hydrochloride, Sitagliptin
Route
Oral Use
Manufacturer
Demo Abee
Origin
EU

Related products

Adiabin

Adiabin

Metformin Hydrochloride, Sitagliptin

Pharmextracta S.P.A
EU
Ansifora Duo

Ansifora Duo

Metformin Hydrochloride, Sitagliptin

Vipharm S.A.
EU
Ansifora Duo

Ansifora Duo

Metformin Hydrochloride, Sitagliptin

Vipharm S.A.
EU
Ansifora Duo

Ansifora Duo

Metformin Hydrochloride, Sitagliptin

Vipharm S.A.
EU